WAYFINDER

• Research type

  Research Study

• Full title

  A Multicentre, Single-arm, Phase 3b Efficacy and Safety Study of Tezepelumab 210 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Participants with Severe Asthma on High-dose Inhaled Corticosteroid plus Long-acting β2 Agonist and Long-term Oral Corticosteroid Therapy (WAYFINDER)

• IRAS ID

  1004972

• Contact name

  Alan Braunton

• Contact email

  alan.braunton@astrazeneca.com

• Sponsor organisation

  AstraZeneca AB

• Eudract number

  2021-005457-85

• Clinicaltrials.gov Identifier

  NCT05274815

• Research summary

  The purpose of this research study is to learn if the investigational drug, tezepelumab, can help people with severe asthma who regularly take oral corticosteroids (such as prednisone or prednisolone) to reduce the dose or even discontinue using oral corticosteroids without losing asthma control. Long-term use of oral corticosteroids is associated with several side effects including osteoporosis, hypertension, depression and a decrease in adrenal gland hormones.

  Approximately 300 patients will take part in this research study. The study will last approximately 2 years. Procedures will include, but are not limited to, blood tests, physical examinations, spirometry, nitric oxide tests and questionnaires.

  AstraZeneca AB are funding the research. The study is planned to run at 4 hospitals in the UK.

• REC name

  London - Surrey Borders Research Ethics Committee

• REC reference

  22/LO/0214

• Date of REC Opinion

  6 Apr 2022

• REC opinion

  Further Information Favourable Opinion